BridgeBio Pharma Inc (BBIO): Next-Year EPS Estimate 127.10%
As of 2026-06-04, BridgeBio Pharma Inc (BBIO) has a next-year EPS growth estimate of 127.10%.
BBIO was first flagged by our screen on 2026-05-26, when analyst consensus for its next-year EPS growth was revised from 128.08% to 128.15%. Current-year growth is projected at 42.24%.
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 127.10%
- EPS growth this year
- 42.24%
- EPS next quarter (est)
- -$0.59
- Last price
- $67.33
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-06-04 | 127.10% | 42.24% | -$0.59 | $67.33 |
| 2026-06-03 | 127.10% | 42.24% | -$0.59 | $65.48 |
| 2026-06-02 | 128.20% | 42.04% | -$0.59 | $63.88 |
| 2026-06-01 | 128.20% | 42.04% | -$0.59 | $65.36 |
| 2026-05-31 | 128.20% | 42.04% | -$0.59 | $66.26 |
| 2026-05-28 | 128.20% | 42.04% | -$0.59 | $68.45 |
| 2026-05-27 | 128.15% | 42.04% | -$0.59 | $66.44 |
| 2026-05-26 | 128.15% | 42.04% | -$0.59 | $67.73 |
| 2026-05-25 | 128.08% | 42.04% | -$0.59 | $69.12 |
| 2026-05-24 | 128.08% | 42.04% | -$0.59 | $69.12 |
| 2026-05-21 | 128.08% | 42.04% | -$0.59 | $70.28 |
| 2026-05-20 | 128.08% | 42.04% | -$0.59 | $68.22 |
| 2026-05-19 | 128.08% | 42.04% | -$0.59 | $66.00 |
| 2026-05-18 | 124.40% | 42.04% | -$0.59 | $65.32 |
| 2026-05-17 | 124.40% | 42.04% | -$0.59 | $66.13 |
| 2026-05-14 | 125.20% | 42.68% | -$0.59 | $69.66 |
| 2026-05-13 | 125.20% | 42.68% | -$0.59 | $69.39 |
| 2026-05-12 | 126.01% | 42.77% | -$0.59 | $65.95 |
| 2026-05-11 | 125.68% | 42.78% | -$0.59 | $64.68 |
| 2026-05-10 | 124.79% | 42.41% | -$0.60 | $67.39 |
| 2026-05-07 | 141.79% | 49.58% | -$0.67 | $67.45 |
| 2026-05-06 | 141.79% | 49.58% | -$0.67 | $68.09 |
| 2026-05-05 | 141.79% | 49.58% | -$0.67 | $68.78 |
| 2026-05-04 | 141.79% | 49.58% | -$0.67 | $68.99 |
| 2026-05-03 | 141.80% | 49.58% | -$0.67 | $68.56 |
| 2026-04-30 | 141.80% | 49.58% | -$0.67 | $71.11 |
| 2026-04-29 | 141.79% | 49.58% | -$0.67 | $70.94 |
| 2026-04-28 | 140.44% | 49.32% | -$0.67 | $69.71 |
| 2026-04-27 | 139.34% | 49.13% | -$0.67 | $74.52 |
| 2026-04-26 | 139.34% | 49.14% | -$0.67 | $73.28 |
Recent News
- StubHub, Jazz Pharmaceuticals upgraded: Wall Street's top analyst callsThe Fly
- Wall Street's Cardiac Bet: Where Diagnostics Meet the MoneyPR Newswire
- BridgeBios Attruby challenges Pfizers Vyndamax legacy in pivotal ATTR trialPharmaceutical Technology
- BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1GlobeNewswire
- Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart FailureGlobeNewswire
- Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart FailureGlobeNewswire
- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- BridgeBio Pharma: Q1 Earnings SnapshotAssociated Press
- BridgeBio Pharma: Q1 Earnings SnapshotAssociated Press
Screen Performance
Aggregate stats across all 1761 tickers our top-EPS-revision screen has flagged over the past 64 days.
- Median return since detection
- +5.1%
- % of tickers in the green
- 62%
- Median return on winners
- +17.5%
- Large revisions captured
- 746
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Frequently Asked Questions
What is BridgeBio Pharma Inc's next-year EPS growth estimate?▾
As of 2026-06-04, BridgeBio Pharma Inc (BBIO) has a next-year EPS growth estimate of 127.10%, based on analyst consensus.
When was the latest EPS estimate revision for BBIO?▾
The most recent revision occurred on 2026-06-03, when analysts adjusted the next-year EPS growth estimate from 128.20% to 127.10%.
What sector and industry does BridgeBio Pharma Inc belong to?▾
BridgeBio Pharma Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. BBIO appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. BridgeBio Pharma Inc (BBIO) appears here because it was detected by our daily top-EPS-revision-performer screen.
← All reports